Literature DB >> 3726992

Failure to cure Leishmania braziliensis guyanensis cutaneous leishmaniasis with oral ketoconazole.

J P Dedet, P Jamet, P Esterre, P M Ghipponi, C Genin, G Lalande.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3726992     DOI： 10.1016/0035-9203(86)90239-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


× No keyword cloud information.
  6 in total

1.  Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum.

Authors:  J P Gangneux; M Dullin; A Sulahian; Y J Garin; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis.

Authors:  Roshan Ramanathan; Kawsar R Talaat; Daniel P Fedorko; Siddhartha Mahanty; Theodore E Nash
Journal:  Am J Trop Med Hyg       Date:  2011-01       Impact factor: 2.345

3.  VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis.

Authors:  Galina I Lepesheva; Tatiana Y Hargrove; Girish Rachakonda; Zdzislaw Wawrzak; Sébastien Pomel; Sandrine Cojean; Pius N Nde; W David Nes; Charles W Locuson; M Wade Calcutt; Michael R Waterman; J Scott Daniels; Philippe M Loiseau; Fernando Villalta
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

4.  Antileishmanial activity of the terpene nerolidol.

Authors:  Denise C Arruda; Fabio Luiz D'Alexandri; Alejandro M Katzin; Silvia R B Uliana
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 5.  Efficacy of azole therapy for tegumentary leishmaniasis: A systematic review and meta-analysis.

Authors:  Endi Lanza Galvão; Ana Rabello; Gláucia Fernandes Cota
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240

6.  Failure of fluconazole in treating cutaneous leishmaniasis caused by Leishmania guyanensis in the Brazilian Amazon: An open, nonrandomized phase 2 trial.

Authors:  Valeska Albuquerque Francesconi; Fabio Francesconi; Rajendranath Ramasawmy; Gustavo Adolfo Sierra Romero; Maria das Graças Costa Alecrim
Journal:  PLoS Negl Trop Dis       Date:  2018-02-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.